Cue Biopharma Inc (NASDAQ:CUE) received encouraging results in the cohort 5 and cohort 4 dosing and got clearance from the SRC (Safety Review Committee). It will commence cohort 6 dosing at 4mg/kg.
Well-positioned to continue development of Cue-101
CEO of Cue Biopharma, Daniel Passeri, said the company is excited about the progress achieved in Phase 1 ongoing dose-escalation clinical study and the encouraging data sets. CSO of Cue Biopharma, Anish Suri, said the company is geared up to execute its development plans for its lead drug candidate CUE-101.
A marginal increase in R&D expenses
Cue Biopharma reported $1.1 million in collaboration revenues in Q2 2020. Its R&D expenses rose by 17.39% YoY to $8.1 million in Q2 2020 because of stock-based compensation, drug production costs, and clinical expenses. However, its general and administrative expenses are almost the same at $3.9 million.
Cue Biopharma holds marketable securities and a cash balance of $85 million by the end of Q2 2020. CFO of Cue Biopharma, Kerri-Ann Millar, said the cash balance and marketable securities allow the company to develop its Immuno-STAT platform that comprises developing CUE-101 into 2022.
CUE-101 to treat HPV+ HNSCC
Cue Biopharma is conducting the dose-escalation study of CUE-101 to cure patients with HPV (human papilloma virus) positive metastatic/ recurrent neck and head squamous cell carcinoma.
Cue Biopharma signed a collaboration accord with the University of Oxford and Dr. Michael Dustin to identify molecular mechanisms responsible for Immuno-STAT Biologics.
Kerri-Ann Millar joined as Chief Finance Officer at Cue Biopharma. Until he is recruited as CFO, Millar served as principal accounting and finance officer since 2018 at Cue BioPharma.
The executive management of Cue Biopharma will present an update on the CUE-101 Phase 1 clinical study to cure HPV+ HNSCC, anticipated milestones, and strategic update on August 31, 2020.
Offers an overview of next-generation NEO-STAT
Cue Biopharma will present its next-generation NEO-STAT and Immuno-STAT on September 9, 2020, at BGHC (Baird Global Healthcare Conference). It will also provide details of its ongoing clinical programs on September 17, 2020, at Morgan Stanley GHC (Global Healthcare Conference).
Cue Biopharma will also take part in the 15Th Annual Biopharma VC (Virtual Conference) during September 9 and 10, 2020.